Meeting
2013 ASCO Annual Meeting
Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop).
Authors
Sanjeeve Balasubramaniam
National Cancer Institute, National Institutes of Health, Bethesda, MD
Sanjeeve Balasubramaniam , Christina Bryla , Christophe E. Redon , Min-Jung Lee , Cody Peer , Jane B. Trepel , Arun Rajan , William Bonner , William Douglas Figg , Antonio Tito Fojo , Richard Piekarz , Giuseppe Giaccone , Susan Elaine Bates
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT00926640
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2527)
DOI
10.1200/jco.2013.31.15_suppl.2527
Abstract #
2527
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).
First Author: Taofeek Kunle Owonikoko
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz
Poster
2018 ASCO Annual Meeting
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.
First Author: Sebastian Ochsenreither
Poster
2017 ASCO Annual Meeting
A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.
First Author: Mark van Bussel